OrphoMed picks up $39 mln Series A
San Francisco Bay Area-based OrphoMed Inc, a clinical stage biopharmaceutical company, has closed $39 million in Series A financing. The round was led by New Enterprise Associates and co-led by Takeda Ventures Inc with participation from return backers Pappas Capital, Relativity Healthcare Partners and the Mario Family Fund. In conjunction with the financing, Dr. Frank Torti, a partner at NEA, and Arthur Pappas, a managing partner of Pappas Capital, have been added to OrphoMed's board of directors.
24 May 2017•1 min read
